Modern to Present at Credit Suisse 28th Annual Healthcare Conference

November 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2019-- Moderna, Inc. (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer, will participate in the Credit Suisse 28th Annual Healthcare Conference in Scottsdale, Arizona on November 13th at 9:45 a.m. ET.

A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005655/en/

Source: Moderna, Inc.

Investors:
Lavina Talukdar
Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com